Evidence map›Paper›PMID 36787143›Full record

ArticleJAMA network open2023

Assessment of Symptom, Disability, and Financial Trajectories in Patients Hospitalized for COVID-19 at 6 Months.

Andrew J Admon, Theodore J Iwashyna, Lee A Kamphuis, Stephanie J Gundel, Sarina K Sahetya, Ithan D Peltan, Steven Y Chang, Jin H Han, Kelly C Vranas, Kirby P Mayer and 10 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Language Barriers and Other Determinants of Post-Intensive Care Unit Follow-Up: A 5-Year Review.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026
    Article
  6. Article
  7. MTHFR allele and one-carbon metabolic profile predict severity of COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 1 country.

Andrew J AdmonDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
Theodore J IwashynaDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
Lee A KamphuisVA Center for Clinical Management Research, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan.
Stephanie J GundelDepartment of Emergency Medicine, Harborview Medical Center, Seattle, Washington.
Sarina K SahetyaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ithan D PeltanDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Intermountain Medical Center, Murray, Utah.
Steven Y ChangRonald Reagan-UCLA Medical Center, Pulmonary & Critical Care Medicine, David Geffen School of Medicine at University of California, Los Angeles.
Jin H HanDepartment of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Kelly C VranasDivision of Pulmonary and Critical Care Medicine, Oregon Health & Science University, Portland.
Kirby P MayerDepartment of Physical Therapy, College of Health Sciences, University of Kentucky, Lexington.
Aluko A HopeDivision of Pulmonary and Critical Care Medicine, Department of Mundeledicine, Oregon Health and Science University School of Medicine, Portland.
Sarah E JolleyDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver.
Ellen CaldwellDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Washington, Seattle.
Max L MonahanPulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Katrina HauschildtPulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Samuel M BrownDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Intermountain Medical Center, Murray, Utah.
Neil R AggarwalDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver.
B Taylor ThompsonDivision of Pulmonary and Critical Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Catherine L HoughDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University School of Medicine, Portland.
National Heart, Lung, and Blood Institute PETAL Network
National Heart Lung and Blood Institute · USUniversity of Colorado Denver · USIntermountain Medical Center · USJohns Hopkins Medicine · USOregon Health & Science University · USUniversity of Kentucky · USUniversity of Michigan–Ann Arbor · USUniversity of Utah · USHarborview Medical Center · USMassachusetts General Hospital · USRonald Reagan UCLA Medical Center · USUniversity of Washington · USVA Ann Arbor Healthcare System · USVA Center for Clinical Management Research · USVA Portland Health Care System · USVA Tennessee Valley Healthcare System · US

Funding

CCC for NHLBI Prevention and Early Treatment of Acute Lung Injury PETAL NetworkU01HL123009 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI FOULKES, ANDREA S, THOMPSON, BOYD TAYLOR · 2014 to 2021
$67.2M
Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
TRAINING IN SOCIAL AND ECONOMIC DEMOGRAPHYT32HD007339 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sarah A. Burgard · 1987 to 2026
$14.9M
Clinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute LungU01HL123022 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SHAPIRO, NATHAN I, TALMOR, DANIEL STUART · 2014 to 2020
$2.9M
Prevention and Early Treatment of Acute Lung InjuryU01HL123004 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHAY, MICHAEL A. · 2014 to 2020
$2.6M
Clinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute LungU01HL123031 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HYZY, ROBERT C, PARK, PAULINE K · 2014 to 2020
$2.6M
Enhancing the Surrogate Informed Consent Process for Critical Care ResearchU01HL123010 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI GINDE, ADIT A., MOSS, MARC · 2014 to 2020
$2.6M
Prevention and Early Treatment of Acute Lung Injury Clinical Trials NetworkU01HL123033 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICE, TODD W · 2014 to 2020
$2.4M
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh - SupplementU01HL123020 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANGUS, DEREK C, YEALY, DONALD M · 2014 to 2020
$2.4M
Long Term Outcomes and Macrophage Biology in Patients with EVALIU01HL123018 · NHLBI · IHC HEALTH SERVICES, INC. · PI BLEDSOE, JOSEPH R, BROWN, SAMUEL MORRIS · 2014 to 2020
$2.4M
Pacific Northwest Clinical Center for the NHLBI PETAL NetworkU01HL123008 · NHLBI · UNIVERSITY OF WASHINGTON · PI HOUGH, CATHERINE LEE, ROBINSON, BRYCE · 2014 to 2020
$2.3M
Acute Lung Injury Group New England Program to Support PETAL Network ResearchU01HL122989 · NHLBI · BAYSTATE MEDICAL CENTER, INC. · PI STEINGRUB, JAY S · 2014 to 2020
$2.2M
HSRD VA IK2 HX003005NCATS NIH HHS UL1 TR002240NHLBI NIH HHS K01 HL140279NHLBI NIH HHS K08 HL148514NHLBI NIH HHS K08 HL155407NHLBI NIH HHS R01 HL155064NHLBI NIH HHS U01 HL122989NHLBI NIH HHS U01 HL122998NHLBI NIH HHS U01 HL123004NHLBI NIH HHS U01 HL123008NHLBI NIH HHS U01 HL123009NHLBI NIH HHS U01 HL123010NHLBI NIH HHS U01 HL123018NHLBI NIH HHS U01 HL123020NHLBI NIH HHS U01 HL123022NHLBI NIH HHS U01 HL123023NHLBI NIH HHS U01 HL123027NHLBI NIH HHS U01 HL123031NHLBI NIH HHS U01 HL123033NIAMS NIH HHS K23 AR079583NICHD NIH HHS T32 HD007339NIMHD NIH HHS L32 MD017732
6 · The paper itself

Abstract

Importance: Individuals who survived COVID-19 often report persistent symptoms, disabilities, and financial consequences. However, national longitudinal estimates of symptom burden remain limited. Objective: To measure the incidence and changes over time in symptoms, disability, and financial status after COVID-19-related hospitalization. Design, Setting, and Participants: A national US multicenter prospective cohort study with 1-, 3-, and 6-month postdischarge visits was conducted at 44 sites participating in the National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Network's Biology and Longitudinal Epidemiology: COVID-19 Observational (BLUE CORAL) study. Participants included hospitalized English- or Spanish-speaking adults without severe prehospitalization disabilities or cognitive impairment. Participants were enrolled between August 24, 2020, and July 20, 2021, with follow-up occurring through March 30, 2022. Exposure: Hospitalization for COVID-19 as identified with a positive SARS-CoV-2 molecular test. Main Outcomes and Measures: New or worsened cardiopulmonary symptoms, financial problems, functional impairments, perceived return to baseline health, and quality of life. Logistic regression was used to identify factors associated with new cardiopulmonary symptoms or financial problems at 6 months. Results: A total of 825 adults (444 [54.0%] were male, and 379 [46.0%] were female) met eligibility criteria and completed at least 1 follow-up survey. Median age was 56 (IQR, 43-66) years; 253 (30.7%) participants were Hispanic, 145 (17.6%) were non-Hispanic Black, and 360 (43.6%) were non-Hispanic White. Symptoms, disabilities, and financial problems remained highly prevalent among hospitalization survivors at month 6. Rates increased between months 1 and 6 for cardiopulmonary symptoms (from 67.3% to 75.4%; P = .001) and fatigue (from 40.7% to 50.8%; P < .001). Decreases were noted over the same interval for prevalent financial problems (from 66.1% to 56.4%; P < .001) and functional limitations (from 55.3% to 47.3%; P = .004). Participants not reporting problems at month 1 often reported new symptoms (60.0%), financial problems (23.7%), disabilities (23.8%), or fatigue (41.4%) at month 6. Conclusions and Relevance: The findings of this cohort study of people discharged after COVID-19 hospitalization suggest that recovery in symptoms, functional status, and fatigue was limited at 6 months, and some participants reported new problems 6 months after hospital discharge.

Indexed as

COVID-19AftercareCohort StudiesFemaleHumansMalePatient DischargeProspective StudiesQuality of LifeSARS-CoV-2

Identifiers

PMID36787143
PMCPMC9929698
OpenAlexW4320709372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.